Clinical trials: Melphalan
Lymphoma
Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
The goal of this clinical research study is to find the highest tolerable dose of vorinostat that can be given with gemcitabine, busulfan, and melphalan with a stem cell transplant.
- Trial name
- NCT01421173
- Testing
- Vorinostat, Gemcitabine, Busulfan
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
This phase III trial compares hematopoietic (stem) cell transplantation (HCT) using mismatched related donors (haploidentical [haplo]) versus matched unrelated donors (MUD) in treating children, adolescents, and young adults with…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT05457556
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Busulfan
- Where
- 63 sites in United States, Australia and 1 more
- Volunteers
- 66 people
- Sponsor
- Children's Oncology Group
Sickle Cell Disease, Graft Versus Host Disease
Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease
To assess the tolerability of the costimulation blocking agent abatacept (CTLA4-Ig) when added to the standard graft versus host disease (GVHD) prophylaxis regimen of a calcineurin inhibitor and methotrexate in patients receiving…
- Trial name
- NCT02867800
- Testing
- Diphenhydramine, Acetaminophen, Methylprednisolone
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Monica Bhatia
Ewing's Sarcoma
Study in Localized and Disseminated Ewing Sarcoma
Ewing Sarcoma Primary objectives: Standard Risk R1: in a randomised trial, to examine whether add-on treatment with zoledronic acid in addition to induction and maintenance chemotherapy improves event-free survival in patients…
- Trial name
- EWING2008 (NCT00987636)
- Testing
- Zoledronic acid, Busulfan, Treosulfan
- Where
- 2 sites in Germany
- Volunteers
- 907 people
- Sponsor
- University Hospital Muenster
High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
This is an international multicenter, open-label, randomized phase III trial including three sequential randomizations to assess efficacy of induction and consolidation chemotherapies and radiotherapy for patients with high-risk…
- Trial name
- HR-NBL2 (NCT04221035)
- Testing
- Vincristine, Carboplatin, Etoposide
- Where
- 142 sites in Australia, Austria and 18 more
- Volunteers
- 800 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Non Malignant Diseases, Immunodeficiencies
Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders
This Phase II pilot study evaluates the safety and effectiveness of reduced-intensity conditioning (RIC) regimens prior to allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric and young adult patients with…
- Conditions
- Non Malignant Diseases, Immunodeficiencies, Hemoglobinopathies
- Trial name
- RIC (NCT01050855)
- Testing
- Reduced-Intensity Conditioning
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Children's Hospital of Philadelphia
Multiple Myeloma
Expanded Natural Killer (NK) Cells for Multiple Myeloma Study
High-dose chemotherapy with melphalan and autologous hematopoietic stem cell transplantation (HSCT) is considered standard treatment for patients with multiple myeloma.
- Trial name
- NCT01040026
- Testing
- Treatment with in vitro expanded haploidentical NK cells
- Where
- Switzerland
- Volunteers
- 10 people
- Sponsor
- University Hospital, Basel, Switzerland
Lymphoma
Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma
The goal of this clinical research study is to learn about the safety and effectiveness of the combination of panobinostat, gemcitabine, busulfan, and melphalan, either with or without rituximab, in patients who have…
- Trial name
- NCT02961816
- Testing
- Palifermin, Panobinostat, Gemcitabine
- Sponsor
- M.D. Anderson Cancer Center